Research programme: antibacterials - AstraZeneca
Alternative Names: AZD 1279; AZD6302Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
- 21 Jun 2011 AZD 5099 has entered clinical development